The hemophilia treatment landscape is evolving faster than ever. In this episode of Global Hemophilia Report, Patrick James Lynch and Dr. Donna DiMichele are joined by Drs. Hermans, Carpenter, and Hansen to break down the emerging class of rebalancing agents—therapies that don’t replace clotting factor, but target new parts of the coagulation cascade.

We explore what these treatments mean for patients, clinics, and shared decision-making around the world. Key takeaways include the urgent need for real-world data, better patient education, and the potential for new therapies to protect joint health in ways never seen before.

Tune in to hear expert insights, practical considerations, and the future of hemophilia care.

Guests:

Dr. Cedric Hermans, MD, - Hemophilia Centre, Saint-Luc University Hospital, Brussels

Dr. Shannon Carpenter, MD - Pediatric Hematology, Kansas City Hemophilia Center:

CJ Hansen BSN, RN - Nurse Coordinator & Program Manager, OSU Comprehensive Cancer Center, Patient Advocate

Senior Advisor: Donna DiMichele, MD

Hosted by: Patrick James Lynch

Featured Advertiser:

Sanofi

Subscribe to the Global Hemophilia Report

Show Notes:

The Bigger Picture in Hemophilia B:

Hemophilia A and hemophilia B are different bleeding disorders with unique pathologies and clinical features.1 Due to the distinct behavior of factor IX, multiple PK parameters should be considered when assessing bleed prevention. Learn how a broader view of PK may influence evaluation of treatment and management for patients with hemophilia B.2,3 Learn more at thebiggerpictureinhemb.com

1. Castaman G, Matino D. Haematologica. 2019;104(9):1702-1709.

2. Dolan G, Benson G, Duffy A, et al. Blood Rev. 2018;32(1):52-60.

3. Mann DM, Stafford KA, Poon M-C, Matino D, Stafford DW. Haemophilia. 2021;27(3):332-339.

Rebalancing Agents and Other Available Treatment Options